Current Report Filing (8-k)
December 02 2022 - 8:14AM
Edgar (US Regulatory)
0001314052
false
0001314052
2022-12-01
2022-12-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December
1, 2022
ANAVEX
LIFE SCIENCES CORP.
(Exact name of registrant as specified in its charter)
Nevada |
001-37606
|
98-0608404
|
(State or other jurisdiction
|
(Commission |
(IRS Employer |
of incorporation) |
File Number) |
Identification No.) |
630
5th Avenue
20th Floor
New York, NY 10111
(Address of principal executive offices) (Zip Code)
1-844-689-3939
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
Trading Symbol |
Name of Each Exchange on Which Registered |
Common Stock, par value $0.001 per share |
AVXL |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On December 1, 2022, Anavex
Life Sciences Corp., a Nevada corporation (the “Company”) issued a press release
(the “Press Release”) providing top line data from its Phase 2b/3 double-blind,
placebo-controlled trial of ANAVEX®2-73 in Alzheimer’s disease. The trial met its primary and key secondary endpoints
with statistically significant results. A copy of the Press Release is attached to this Current Report on Form 8-K as Exhibit 99.1 and
incorporated herein by reference.
Item
9.01 |
Financial
Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ANAVEX LIFE SCIENCES CORP. |
|
|
|
By: |
|
|
|
/s/Christopher
Missling |
|
|
Name: Christopher Missling, PhD |
|
|
Title: Chief Executive Officer |
|
|
|
Date: December 2, 2022 |
|
|
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Apr 2023 to Apr 2024